6:12 PM
 | 
Oct 27, 2009
 |  BC Extra  |  Company News

Mixed bag for ABthrax

In its review of a BLA for ABthrax raxibacumab to treat inhalation anthrax, FDA's Anti-Infective Drugs Advisory Committee supported the overall efficacy of the mAb from Human Genome Sciences Inc. (NASDAQ:HGSI) but recommended that additional studies be requested. The committee voted 17-6 with one abstention that the evidence from animal studies supported the conclusion that ABthrax was reasonably likely to have efficacy in humans.

The panel was...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >